Effects of Diabetes Related Therapy on Cognitive Function

doi:10.12114/j.issn.1007-9572.2018.00.321

Abstract

Abstract: Dementia and mild cognitive impairment are increasingly affecting people's health，but effective treatment have not been found.Researches have shown that diabetes mellitus was an independent risk factor for cognitive impairment.Diabetes and dementia have a lot of common pathological basis.Therefore，diabetes-related therapy may have a potential impact on the cognitive function in patients with diabetes mellitus，which is important for many diabetic patients with cognitive impairment.This article explored the effects of diabetes-related therapy on cognitive function and sought for beneficial treatment methods.It will provide ideas and references for further treatment and research in this area.

Key words: Mild cognitive impairment, Dementia, Diabetes mellitus, Treatment

摘要： 痴呆与轻度认知功能障碍正日益影响人群健康，但目前尚未找到确切有效的治疗方法。已有研究显示糖尿病是认知功能障碍的独立危险因素。糖尿病与痴呆具有很多共同的病理基础，因此，糖尿病相关治疗可能对患者认知功能产生潜在影响，对于众多糖尿病合并认知功能障碍人群有重要意义。本文通过探讨糖尿病相关治疗对认知功能的影响，寻找有益的治疗方法，为下一步治疗和研究提供思路和借鉴。

关键词: 轻度认知障碍, 痴呆, 糖尿病, 治疗

WEI Wei,LU Yuan. Effects of Diabetes Related Therapy on Cognitive Function　[J]. Chinese General Practice, 2019, 22(12): 1501-1506. DOI: 10.12114/j.issn.1007-9572.2018.00.321.
魏魏,陆媛. 糖尿病相关治疗对认知功能影响的研究进展[J]. 中国全科医学, 2019, 22(12): 1501-1506. DOI: 10.12114/j.issn.1007-9572.2018.00.321.

References

［1］贾建平．中国痴呆与认知障碍诊治指南（2015年版）［M］．北京：人民卫生出版社，2015：1．
JIA J P.Guidelines for diagnosis and treatment of dementia and cognitive impairment in China （2015 Edition）［M］．Beijing：People's Medical Publishing House，2015：1.
［2］FERRI C P，PRINCE M，BRAYNE C，et al．Global prevalence of dementia：a Delphi consensus study［J］．Lancet，2005，366（9503）：2112-2117．DOI：10.1016/S0140-6736（05）67889-0.
［3］FENG Q P，LI X J，SU Y，et al．Study on the relation of TCF7L2rs7903146T／C and rs7901695T／C SNPs with susceptibility to type 2 diabetes mellitus in Inner Mongolia Han people［J］．Chinese Journal of Diabetes，2012，20（10）：721-724．DOI：10.3969/j.issn.1006-6187.2012.10.001.
［4］WENNBERG A M，GOTTESMAN R F，KAUFMANN C N，et al．
Diabetes and cognitive outcomes in a nationally representative sample：the National Health and Aging Trends Study［J］．Int Psychogeriatr，2014，26（10）：1729-1735．DOI：10.1017/S1041610214001380.
［5］GUDALA K，BANSAL D，SCHIFANO F，et al．Diabetes mellitus and risk of dementia：a meta-analysis of prospective observational studies［J］．J Diabetes Investig，2013，4（6）：640-650．DOI：10.1111/jdi.12087.
［6］LI L，WANG Y，YAN J，et al．Clinical predictors of cognitive decline in patients with mild cognitive impairment：the Chongqing aging study［J］．J Neurol，2012，259（7）：1303-1311．DOI：10.1007/s00415-011-6342-0.
［7］LI L，HOLSCHER C.Common pathological processes in Alzheimer disease and type 2 diabetes：a review［J］．Brain Res Rev，2007，56（2）：384-402．DOI：10.1016/j.brainresrev.2007.09.001.
［8］MOHEET A，MANGIA S，SEAQUIST E R.Impact of diabetes on cognitive function and brain structure［J］．Ann N Y Acad Sci，2015，1353：60-71．DOI：10.1111/nyas.12807.
［9］PALTA P，SCHNEIDER A L，BIESSELS G J，et al．Magnitude of cognitive dysfunction in adults with type 2 diabetes：a meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains［J］．Int Neuropsychol Soc，2014，20（3）：278-291．DOI：10.1017/S1355617713001483.
［10］MANSCHOT S M，BRANDS A M，VAN DER GROND J，et al．Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes［J］．Diabetes，2006，55（4）：1106-1113.
［11］LOURIDA I，SONI M，THOMPSON-COON J，et al．Mediterranean diet，cognitive function，and dementia：a systematic review［J］．Epidemiology ，2013，24：479-489．DOI：10.1097/EDE.0b013e3182944410.
［12］FOTUHI M，MOHASSEL P，YAFFE K.Fish consumption，long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease：a complex association［J］．Nat Clin PractNeurol，2009，5：140-152．DOI：10.1038/ncpneuro1044.
［13］BLASKO I，HINTERBERGER M，KEMMLER G，et al．Conversion from mild cognitive impairment to dementia：influence of folic acid and vitamin B12 use in the VITA cohort［J］．Nutr Health Aging，2012，16（8）：687-694．DOI：10.1007/s12603-012-0051-y.
［14］DEVORE E E，KANG J H，BRETELER M M，et al．Dietary intakes of berries and flavonoids in relation to cognitive decline［J］．Ann Neurol，2012，72（1）：135-143．DOI：10.1002/ana.23594.
［15］VOSS M W，VIVAR C，KRAMER A F，et al．Bridging animal and human models of exercise-induced brain plasticity［J］．Trends Cogn Sci，2013，17（10）：525-544．DOI：10.1016/j.tics.2013.08.001.
［16］Look AHEAD Research Group，WING R R.Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus：four-year results of the look ahead trial［J］．Arch Intern Med，2010，170（17）：1566 -1575．DOI：10.1001/archinternmed.2010.334.
［17］ZHENG G，XIA R，ZHOU W，et al．Aerobic exercise ameliorates cognitive function in older adults with mild cognitive impairment：a systematic review and meta-analysis of randomised controlled trials［J］．Br J Sports Med，2016 ，50（23）：1443-1450．DOI：10.1136/bjsports-2015-095699.
［18］RAJANI S，ARCHANA R，INDLA Y R，et al．Beneficial effects of yogasanas and pranayama in limiting the cognitive decline in type 2 diabetes［J］．Natl J Physiol Pharm Pharmacol，2017，7（3）：232-235．DOI：10.5455/njppp.2017.7.0825508092016.
［19］FIATARONE SINGH M A，GATES N，SAIGAL N，et al．The Study of Mental and Resistance Training（SMART） study-resistance training and/or cognitive training in mild cognitive impairment：a randomized，double-blind，double-sham controlled trial［J］．J Am Med Dir Assoc，2014，15（12）：873-880．DOI：10.1016/j.jamda.2014.09.010.
［20］TEIXEIRA R B，MARINS J C，DE SA JUNIOR A R，et al．Improved cognitive，affective and anxiety measures in patients with chronic systemic disorders following structured physical activity［J］．Diab Vasc Dis Res，2015，12（6）：445-454．DOI：10.1177/1479164115602651.
［21］TEIXEIRA R B，MARINS J C B，AMORIM P R S，et al．Evaluating the effects of exercise on cognitive function in hypertensive and diabetic patients using the mental test and training system［J］．World J Biol Psychiatry，2017，28：1-10．DOI：10.1080/15622975.2017.1337222.
［22］LUCHSINGER J A，PALMAS W，TERESI J A，et al．Improved diabetes control in the elderly delays global cognitive decline［J］．J Nutr Health Aging，2011，15（6）：445-449.
［23］PINTANA H，APAIJAI N，PRATCHAYASAKUL W，et al．Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats［J］．Life Sci，2012，91（11/12）：409-414．DOI：10.1016/j.lfs.2012.08.017.
［24］HAFFINER S，TEMPROSA M，CRANDALL J，et al．Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance［J］．Diabetes，2005，54（5）：1566-1572.
［25］CHEN F，DONG R R，ZHONG K L，et al．Antidiabetic drugs restore abnormal transport of amyloid-β across the blood-brain barrier and memory impairment in db/db mice［J］．Neuropharmacology，2016，101：123-136．DOI：10.1016/j.neuropharm.2015.07.023.
［26］NG T P，FENG L，YAP K B，et al．Long-term metformin usage and cognitive function among older adults with diabetes［J］．J Alzheimers Dis，2014，41（1）：61-68．DOI：10.3233/JAD-131901.
［27］梁城铭，安刚，韩昕彤，等．二甲双胍联合有氧运动对2型糖尿病患者认知功能的改善作用［J］．中国老年学杂志，2017，37（12）：2958-2959．DOI：10.3969/j.issn.1005-9202.2017.12.043.
LIANG C M，AN G，HAN X T，et al．Effect of metformin combined with aerobic exercise on cognitive function in patients with type 2 diabetes mellitus［J］．Chinese Journal of Gerontology，2017，37（12）：2958-2959．DOI：10.3969/j.issn.1005-9202.2017.12.043.
［28］LIN Y，WANG K，MA C，et al．Evaluation of metformin on cognitive improvement in patients with non-dementia vascular cognitive impairment and abnormal glucose metabolism［J］．Front Aging Neurosci，2018，27（10）：227．DOI：10.3389/fnagi.2018.00227.
［29］HSU C C，WAHLQVIST M L，LEE M S，et al．Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin［J］．J Alzheimers Dis，2011，24（3）：485-493．DOI：10.3233/JAD-2011-101524.
［30］IMFELD P，BODMER M，JICK S S，et al．Metformin，other antidiabetic drugs，and risk of Alzheimer's disease：a population-based case-control study［J］．J Am Geriatr Soc，2012，60（5）：916-921．DOI：10.1111/j.1532-5415.2012.03916.x.
［31］MOORE E M，MANDER A G，AMES D，et al．Increased risk of cognitive impairment in patients with diabetes is associated with metformin ［J］．Diabetes Care，2013，36（10）：2981-2987．DOI：10.2337/dc13-0229.
［32］KHANFAR M A，ABUKHADER M M，ALQTAISHAT S，et al．
Pharmacophore modeling，homology modeling，and in silico screening reveal mammalian target of rapamycin inhibitory activities for sotalol，glyburide，metipranolol，sulfamethizole，glipizide，and pioglitazone［J］．Mol Graph Model，2013，42：39-49．DOI：10.1016/j.jmgm.2013.02.009.
［33］OSBORNE C，WEST E，NOLAN W，et al．Glimepiride protects neurons against amyloid-beta-induced synapse damage［J］．Neuropharmacology，2016，101：225-236．DOI：10.1016/j.neuropharm.2015.09.030.
［34］綦雯雯，贾凯英，孙达，等．吡格列酮对糖尿病大鼠中枢神经系统11β-羟类固醇脱氢酶1 型表达的影响［J］．神经疾病与精神卫生，2017，17（3）：184-186．DOI：10.3969/j.issn.1009-6574.2017.03.009.
QI W W，JIA K Y，SUN D，et al．Effects of pioglitazone on expressions of 11β-hydroxysteroid dehydrogenase type 1 in central nervous system of diabetic rats［J］．Journal of Neuroscience and Mental Health，2017，17（3）：184-186．DOI：10.3969/j.issn.1009-6574.2017.03.009.
［35］SEARCY J L，PHELPS J T，PANCANI T，et al．Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease［J］．Alzheimers Dis，2012，30（4）：943-961．DOI：10.3233/JAD-2012-111661.
［36］SATO T，HANYU H，HIRAO K，et al．Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease［J］．Neurobiol Aging，2011，32（9）：1626-1633．DOI：10.1016/j.neurobiolaging.2009.10.009.
［37］于海燕，王群松，张梓威，等．吡格列酮治疗2 型糖尿病轻度认知功能障碍患者的临床疗效［J］．中国老年学杂志，2017，37（17）：4224-4226．DOI：10.3969/j.issn.1005-9202.2017.17.026.
YU H Y，WANG Q S，ZHANG Z W，et al．Clinical efficacy of pioglitazone in the treatment of mild cognitive impairment in type 2 diabetes mellitus ［J］．Chinese Journal of Geriatrics，2017，37（17）：4224-4226．DOI：10.3969/j.issn.1005-9202.2017.17.026.
［38］LU C H，YANG C Y，LI C Y，et al．Lower risk of dementia with pioglitazone，compared with other second-line treatments，in metformin-based dual therapy：a population-based longitudinal study［J］．Diabetologia，2018，61（3）：562-573．DOI：10.1007/s00125-017-4499-5.
［39］TALBOT K.Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs［J］．Neurodegener Dis Manag，2014，4（1）：31-40．DOI：10.2217/nmt.13.73.
［40］CHEN S，LIU AR，AN FM，et al．Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4［J］．Age（Dordr），2012，34：1211-1224．DOI：10.1007/s11357-011-9303-8.
［41］HOLSCHER C.Central effects of GLP-1：new opportunities for treatments of neurodegenerative diseases［J］．J Endocrinol，2014，221（1）：T31-41．DOI：10.1530/JOE-13-0221.
［42］MCCLEAN P L，PARTHSARATHY V，FAIVRE E，et al．The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease［J］．Neurosci，2011，31（17）：6587-6594．DOI：10.1523/JNEUROSCI.0529-11.2011.
［43］GEJL M，GJEDDE A，EGEFJORD L，et al．In Alzheimer's disease，6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism：randomized，placebo-controlled，double-blind clinical trial［J］．Front Aging Neurosci，2016 ，8：108．DOI：10.3389/fnagi.2016.00108.
［44］洪世华，吴菊琴，方向南，等．GLP-1受体激动剂对2 型糖尿病合并阿尔茨海默病患者认知功能的影响［J］．中国当代医药，2016 ，23（29）：60-62.
HONG S H，WU J Q，FANG X N，et al．Influence of GLP-1 receptor stimulant on the cognitive function in patients with type 2 diabetes complicated with Alzheimer disease ［J］．China Modern Medicine，2016，23（29）：60-62.
［45］张萌，张璐，李玉中，等．利拉鲁肽对2型糖尿病患者认知功能的影响及可能机制［J］．中华糖尿病杂志，2014，6（2）：91-96．DOI：10.3760/cma.j.issn.1674-5809.2014.02.007.
ZHANG M，ZHANG L，LI Y Z，et al.Effects of liraglutide on the cognitive function in patients with type 2 diabetes mellitus and the underlying mechanism ［J］．Chin J Diabetes Mellitus，2014，6（2）：91-96．DOI：10.3760/cma.j.issn.1674-5809.2014.02.007.
［46］CAI H Y，HOLSCHER C，YUE X H，et al．Lixisenatide rescues spatial memory and synaptic plasticity from amyloid beta protein-induced impairments in rats［J］．Neuroscience，2014，277：6-13．DOI：10.1016/j.neuroscience.2014.02.022.
［47］PIPATPIBOON N，PINTANA H，PRATCHAYASAKUL W，et al．
DPP4-inhibitor improves neuronal insulin receptor function，brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption［J］．Eur J Neurosci，2013，37（5）：839-849．DOI：10.1111/ejn.12088.
［48］KOSARAJU J，MURTHY V，KHATWAL R B，et al．Vildagliptin：an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease［J］．J Pharm Pharmacol，2013，65（12）：1773-1784．DOI：10.1111/jphp.12148.
［49］黄文湧，韩志琰，杨敬源，等．老年糖尿病患者降糖治疗与认知功能的关系［J］．中国糖尿病杂志，2009，17（11）：850-852．DOI：10.3969/j.issn.1006-6187.2009.11.017.
HUANG W Y，HAN Z Y，YANG J Y，et al．The relationship between diabetic treatment and cognitive function among the elderly［J］．Chin J Diabetes，2009，17（11）：850-852．DOI：10.3969/j.issn.1006-6187.2009.11.017.
［50］ARAKI A.Insulin therapy in elderly patients with diabetes mellitus［J］．Nihon Ronen Igakkai Zasshi，2004，41（2）：157-160.
［51］RDZAK G M，ABDELGHANY O.Does insulin therapy for type 1 diabetes mellitus protect against Alzheimer's disease？［J］．Pharmacotherapy，2014，34（12）：1317-1323．DOI：10.1002/phar.1494.
［52］杨雁，马德琳，王玉萍，等．鼻腔滴入胰岛素改善2型糖尿病大鼠海马阿尔茨海默病样改变［J］．中国病理生理杂志，2013，29（1）：56-61．DOI：10.3969/j.issn.1000-4718.2013.01.009.
YANG Y，MA D L，WANG Y P，et al．Intranasal insulin treatment ameliorates Alzheimer disease-like changes in hippocampus in a rat model of type 2 diabetes［J］．Chinese Journal of Pathophysiology，2013，29（1）：56-61．DOI：10.3969/j.issn.1000-4718.2013.01.009.
［53］FREIHERR J，HALLSCHMID M，FREY W H 2nd，et al．Intranasal insulin as a treatment for Alzheimer's disease：a review of basic research and clinical evidence［J］．CNS Drugs，2013，7（7）：505-514．DOI：10.1007/s40263-013-0076-8.
［54］CRAFT S，BAKER L D，MONTINE T J ，et al．Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment：a pilot clinical trial［J］．Arch Neurol，2012 ，69（1）：29-38．DOI：10.1001/archneurol.2011.233.
［55］FEART C，SAMIERI C，RONDEAU V，et al．Adherence to a Mediterranean diet，cognitive decline，and risk of dementia［J］．JAMA，2009 ，302（6）：638-648．DOI：10.1001/jama.2009.1146.
［56］ANGEVAREN M，AUFDEMKAMPE G，VERHAAR H J，et al．Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment［J］．Cochrane Database Syst Rev，2008，16（3）：CD005381．DOI：10.1002/14651858.CD005381.pub3.
［57］PODOLSKI N，BRIXIUS K，PREDEL H G，et al．Effects of regular physical activity on the cognitive performance of type 2 diabetic patients：a systematic review［J］．Metab Syndr Relat Disord，2017，15（10）：481-493．DOI：10.1089/met.2017.0120.
［58］中国痴呆与认知障碍诊治指南写作组.2018中国痴呆与认知障碍诊治指南（四）：认知障碍疾病的辅助检查［J］．中华医学杂志，2018，98（15）：1130-1142．DOI：10.3760/cma.j.issn.0376-2491.2018.15.003.
Chinese dementia and cognitive impairment guidelines writing group.2018 guidelines for diagnosis and treatment of dementia and cognitive impairment in China（four）：auxiliary examination for cognitive impairment［J］．Natl Med J China，2018，98（15）：1130-1142．DOI：10.3760/cma.j.issn.0376-2491.2018.15.003.
［59］Consensus report of the Working Group on："Molecular and Biochemical Markers of Alzheimer's Disease".The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group ［J］．Neurobiol Aging，1998，19（2）：109-116.
［60］中国痴呆与认知障碍诊治指南写作组.2018中国痴呆与认知障碍诊治指南（二）：阿尔茨海默病诊治指南［J］．中华医学杂志，2018，98（13）：971-977．DOI：10.3760/cma.j.issn.0376-2491.2018.13.004.
Chinese dementia and cognitive impairment guidelines writing group.2018 guidelines for diagnosis and treatment of dementia and cognitive impairment in China（two）：guidelines for the diagnosis and treatment of alzheimer's disease ［J］．Natl Med J China，2018，98（13）：971-977．DOI：10.3760/cma.j.issn.0376-2491.2018.13.004.

[1]	YAO Yuzhong, MA Xiaojun, SONG Huan, ZHONG Yu. The Management Effect of Diabetes "1358 model" on Community Diabetes Patients Based on "Precision Management Combining General Care and Specialty Care" [J]. Chinese General Practice, 2023, 26(34): 4308-4314.
[2]	WANG Zhe, DONG Zhihao, ZHENG Hao, KONG Wencheng, ZHANG Yukuan, ZHANG Qiuyue, HAN Jing. Construction of Optimized Treatment Plan of Acupuncture for Migraine Based on Entropy Weight-TOPSIS Method [J]. Chinese General Practice, 2023, 26(34): 4336-4342.
[3]	LI Dianjiang, PAN Enchun, SUN Zhongming, WEN Jinbo, WANG Miaomiao, WU Ming, SHEN Chong. The Current Status and Influencing Factors of Clinical Inertia in Type 2 Diabetes Patients in Community [J]. Chinese General Practice, 2023, 26(34): 4296-4301.
[4]	LIN Kai, YAO Mi, CHEN Zhang, JI Xinxin, LIN Runqi, CHEN Yongsong, Sim MOIRA. Conceptual Framework and Responding Approach of Treatment Burden of Type 2 Diabetes: a Video Recording-based Analysis [J]. Chinese General Practice, 2023, 26(34): 4302-4307.
[5]	YANG Hui, HU Ruwei, LIU Ruqing, LU Junfeng, WU Jinglan. Relationship between Community Health Service Experience and Glycemic Control Outcomes in Patients with Diabetes Mellitus [J]. Chinese General Practice, 2023, 26(34): 4290-4295.
[6]	WANG Jie, LI Shiming, WEI Shifei, WANG Ningli. Importance of the Role of Primary Care in Myopia Prevention and Control Behavioral Intervention among Children [J]. Chinese General Practice, 2023, 26(33): 4213-4217.
[7]	XIN Gongkai, CONG Xin, YUAN Lei, CHENG Yuetong, NI Cuiping, ZHANG Weiwei, ZHANG Pingping, LIU Yu. Research Progress on Comprehensive Assessment Tools for the Elderly with Dementia [J]. Chinese General Practice, 2023, 26(33): 4103-4109.
[8]	ZHANG Juan, LI Haifen, LI Xiaoman, YAO Miao, MA Huizhen, MA Qiang. Construction of Recurrence Risk Prediction Model for Diabetic Foot Ulcer on the Basis of Logistic Regression, Support Vector Machine and BP Neural Network Model [J]. Chinese General Practice, 2023, 26(32): 4013-4019.
[9]	GAO Jing, ZHOU Shangcheng, GAO Sande, ZOU Guanyang, CHEN Yingyao. Health-related Quality of Life and Its Influencing Factors in Patients with Prevention of Disease in Traditionnal Chinese Medicine based on EQ-5D-5L Scale [J]. Chinese General Practice, 2023, 26(32): 4043-4050.
[10]	LU Guangqi, ZHUANG Minghui, ZHU Liguo, GAO Jinghua, WEI Xu, LI Luguang, YU Jie. Interpretation of Best Practices for Minimally Invasive Lumbar Spinal Stenosis Treatment 2.0 (MIST) : Consensus Guidance from the American Society of Pain and Neuroscience (ASPN) in 2022 [J]. Chinese General Practice, 2023, 26(32): 3995-4000.
[11]	LI Qian, ZHANG Yunshu, YAN Baoping, WANG Jian, MA Yanjuan, WANG Yuan, QIN Yingjie, NA Long, REN Zhiyong, SUN Junwei, DENG Huaili, MA Hongjun, QU Xuehui, ZHOU Nan, SI Tianmei. Efficacy and Safety of Risperidone Microspheres for Injection (Ⅱ) in the Treatment of Patients with Acute Schizophrenia [J]. Chinese General Practice, 2023, 26(32): 4007-4012.
[12]	LOU Zheng, LIU Ying, REN Jingjing. Visits for Medically Unspecified Disease in General Internal Medicine Clinics of County General Hospitals [J]. Chinese General Practice, 2023, 26(31): 3945-3950.
[13]	CHENG Jingwei, QIAO Junjun, YIN Zhen, HU Junpeng, WANG Qinghe, LIU Yangqing, WANG Yanfang. Interpretation of ISPAD Clinical Practice Consensus Guidelines 2022: Exercise in Children and Adolescents with Diabetes [J]. Chinese General Practice, 2023, 26(30): 3719-3724.
[14]	ZHU Lin, GUO Yankui, GAO Chen, CHEN Xuezhi, WANG Fashuai. Efficacy of Western Medicine, Chinese Patent Medicine and Their Combination on Post-stroke Insomnia: a Network Meta-analysis [J]. Chinese General Practice, 2023, 26(30): 3823-3832.
[15]	ZHOU Sijing, LUO Bangan, CAO Hui, ZHANG Xi, WANG Dongxin. Epidemiological Characteristics of Dementia and Its Correlation with Multimorbidity among Residents Aged 65 and Above [J]. Chinese General Practice, 2023, 26(29): 3616-3621.